A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Advanced/Recurrent Solid Tumors
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197
Yes
Study Director
Study Director
Kyowa Hakko Kirin Company, Limited
Japan: Ministry of Health, Labor and Welfare
ARQ 197-0701
NCT00609921
January 2008
Name | Location |
---|